Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4589954 | 0.90 | LMNA (0.32) | LMNA | |
| SCHEMBL4588304 | 0.85 | TSHR (0.30) | TSHRMAPK1 | |
| SCHEMBL4589208 | 0.78 | LMNA (0.36) | LMNASMN1; SMN2 | |
| SCHEMBL4590109 | 0.76 | LMNA (0.38) | LMNASMN1; SMN2 | |
| SCHEMBL4588298 | 0.75 | — | — | |
| SCHEMBL5555241 | 0.72 | LMNA (0.38) | LMNATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL22645201 | 0.70 | TSHR (0.46) | LMNATSHRMAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11394886 | 0.69 | TSHR (0.45) | LMNATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL4589205 | 0.68 | — | — | |
| SCHEMBL11399810 | 0.68 | TSHR (0.35) | LMNATSHRMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7385054-B2 | Trimeric, macrocyclically substituted halo-benzene derivatives | SCHERING AG (DE) | 2008-06-10 | — | — | US | disclosed |
| US-20060154989-A1 | Trimeric, macrocyclically substituted halo-benzene derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154989-A1 | Trimeric, macrocyclically substituted halo-benzene derivatives | BOLA2; BOLA2B, BRI3BP, ARRB1 | LMNA 2174/4885TSHR 46/4885MAPK1 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.